Scientific Advisor: Pasi A. Jänne, M.D.,Ph.D.
Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University.
Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award, a member of the 2010 AACR Team Science Award and the recipient for the 2018 Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship and in 2018 the European Society of Medical Oncology Translational Research Award and the Outstanding Investigator Award (R35) from the National Cancer Institute.
Pasi A. Jänne, M.D.,Ph.D.
Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University.
Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award, a member of the 2010 AACR Team Science Award and the recipient for the 2018 Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship and in 2018 the European Society of Medical Oncology Translational Research Award and the Outstanding Investigator Award (R35) from the National Cancer Institute.
